FDA approved 46 drugs in 2017, a 21-year high; pilot program tests using home care to reduce emergency department visits; a look at how increasing prices, not increased use of services, has caused American healthcare spending to grow so much faster than peer nations.
In 2017, the FDA approved 46 new drugs, which was more than double the amount approved in 2016. According to Reuters, this represented a 21-year high for FDA drug approvals in 1 year, and the number does not include the first gene therapies approved, which are part of a different category. The FDA has been able to accelerate the approval process by using the breakthrough therapy designation.
A new pilot program in Washington, DC, is virtually connecting Medicaid patients who can’t or won’t visit the clinic to primary care. The program sends a medical assistant to the home to connect the patient with the clinic, according to NPR. The idea is to develop relationships with patients who aren’t going to the doctor’s office and reduce the use of unnecessary visits to the emergency department (ED). In addition, the DC council is considering a way to reimburse for these types of visits.
Just a few decades ago, American healthcare spending was closer to that of comparable nations. But today, the country spends almost twice as much. The New York Times blog The Upshot explains that the price, not the use, of healthcare in America is the problem. Americans are actually using the same amount of healthcare as people in peer countries—they just pay a lot more for those services. Research has shown that the growth in American healthcare spending is almost entirely from growth in prices and that US hospital prices are 60% higher than European prices.
Disparities in Telehealth Access Undermine Adoption Among Patients With Schizophrenia
January 16th 2025The COVID-19 pandemic accelerated the widespread adoption of telemental health care, and new research indicates significant racial and ethnic disparities in access to this technology among Medicaid beneficiaries with schizophrenia.
Read More
Study Suggests Postdischarge Care Needs Targeted, Multifaceted Approaches
January 15th 2025The findings challenge the effectiveness of these widely used transitional care interventions and suggest a need for more targeted, multifaceted approaches to address the needs of higher-risk patients.
Read More
Frameworks for Advancing Health Equity: Pharmacy Support for Non-Hodgkin Lymphoma
December 19th 2024Rachael Drake, pharmacy technician coordinator, University of Kansas Health System, explains how her team collaborates with insurance companies and providers to support treatment access for patients with non-Hodgkin lymphoma.
Listen